GlassScriptPhysician profile
Russell R Bond
NPI 1871608406
$634.76
in general payments reported to CMS, 2019-2025
13 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $54.92 · 2021: $110 · 2022: $34.80 · 2024: $57.31 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $179.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $208.62 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $94.13 | 2022-2025 | Xeomin |
| Allergan, INC. | $89.27 | 2019-2021 | |
| Abbvie INC. | $65.60 | 2022-2025 | |
| Vertex Pharmaceuticals Incorporated | $41.19 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $33.97 | 2021 | |
| Bioventus LLC | $19.68 | 2019 | |
| Zimmer Biomet Holdings, INC. | $16.46 | 2020 | |
| Merz North America, INC. | $14.28 | 2019 | |
| Boston Scientific Corporation | $14.14 | 2019 | |
| Medtronic, INC. | $13.62 | 2024 | Intellis Adaptivestim |
| Biodelivery Sciences International, INC. | $12.81 | 2019 | |
| Pfizer INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Bond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.